Feature Articles

Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths

Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths

Does the failure of pembrolizumab in multiple myeloma clinical trials imply checkpoint inhibition is unlikely to work for patients with the disease?

Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.

In Focus: Ponatinib for Chronic Myeloid Leukemia

In Focus: Ponatinib for Chronic Myeloid Leukemia

Ponatinib is highly effective among patients with CML, but the optimal dose is still being determined. Current trials are evaluating an initial dose of 30 mg, with a reduction to 15 mg when a response is achieved.

Hematologic Cancers Resources

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters